Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.
Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Guzmán D, Guàrdia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE. Herrera-Guzmán I, et al. J Psychiatr Res. 2009 Jun;43(9):855-63. doi: 10.1016/j.jpsychires.2008.10.015. Epub 2009 Jan 6. J Psychiatr Res. 2009. PMID: 19128810 Clinical Trial.
Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Abarca JE, Herrera-Guzmán D, Montelongo-Pedraza P, Padrós Blázquez F, Peró-Cebollero M, Guàrdia-Olmos J. Herrera-Guzmán I, et al. J Affect Disord. 2010 Jun;123(1-3):341-50. doi: 10.1016/j.jad.2009.10.009. Epub 2009 Nov 6. J Affect Disord. 2010. PMID: 19896719
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.
Herrera-Guzmán I, Herrera-Abarca JE, Gudayol-Ferré E, Herrera-Guzmán D, Gómez-Carbajal L, Peña-Olvira M, Villuendas-González E, Joan GO. Herrera-Guzmán I, et al. Psychiatry Res. 2010 May 30;177(3):323-9. doi: 10.1016/j.psychres.2010.03.006. Epub 2010 Apr 10. Psychiatry Res. 2010. PMID: 20385412
The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
Gudayol-Ferré E, Herrera-Guzmán I, Camarena B, Cortés-Penagos C, Herrera-Abarca JE, Martínez-Medina P, Cruz D, Hernández S, Genis A, Carrillo-Guerrero MY, Avilés Reyes R, Guàrdia-Olmos J. Gudayol-Ferré E, et al. J Affect Disord. 2010 Dec;127(1-3):343-51. doi: 10.1016/j.jad.2010.06.002. Epub 2010 Jul 2. J Affect Disord. 2010. PMID: 20584552
Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
Gudayol-Ferré E, Herrera-Guzmán I, Camarena B, Cortés-Penagos C, Herrera-Abarca JE, Martínez-Medina P, Asbun-Bojalil J, Lira-Islas Y, Reyes-Ponce C, Guàrdia-Olmos J. Gudayol-Ferré E, et al. Hum Psychopharmacol. 2012 Nov;27(6):577-86. doi: 10.1002/hup.2267. Hum Psychopharmacol. 2012. PMID: 24446536 Clinical Trial.
24 results